Galapagos Announces Half Year 2005 Results
August 12, 2005 02:24 ET
|
Galapagos Genomics
Mechelen, Belgium, Aug. 12, 2005 (PRIMEZONE) -- Galapagos:
- Financials on target for 2005 increased annual revenues and
cash burn of around 7 million euro
- Initial public offering...
Galapagos and High Q Foundation Announce in Principle Agreement on 2.4 million Alliance to Discover Drug Targets for Huntington Disease
August 12, 2005 02:18 ET
|
Galapagos Genomics
MECHELEN, Belgium and NEW YORK, Aug. 12, 2005 (PRIMEZONE) -- The High Q Foundation Inc., a foundation that supports research aimed at finding diagnoses, treatments, cures and preventions of...
Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University Collaborate in Arthritis Drug Discovery Program
August 10, 2005 02:12 ET
|
Galapagos Genomics
MECHELEN, Belgium, Aug. 10, 2005 (PRIMEZONE) -- Galapagos NV, ZoBio BV, Pyxis Discovery BV and Leiden University announced today the formation of a four-way collaboration to pursue a small molecule...
Galapagos to Release Half Year Results on Friday, August 12
August 02, 2005 03:36 ET
|
Galapagos Genomics
MECHELEN, Belgium, Aug. 2, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company (Euronext:GLPG) announced today that it will release its financial results for the first half of...
Galapagos Signs Research Collaboration Agreement
July 06, 2005 02:10 ET
|
Galapagos Genomics
MECHELEN, Belgium, July 6, 2005 (PRIMEZONE) -- Galapagos announced today that it has entered into a research collaboration with Novartis Pharmaceuticals UK Limited. Under the agreement, Galapagos'...
Galapagos and Celera Genomics Sign Gene Function Analysis Agreement
June 20, 2005 02:05 ET
|
Galapagos Genomics
ROCKVILLE, M.D. and MECHELEN, Belgium, June 20, 2005 (PRIMEZONE) -- Galapagos today announced that it has entered into a services agreement with Celera Genomics Group (NYSE:CRA), an Applera...
Galapagos Announces Changes to Board of Directors
May 24, 2005 02:06 ET
|
Galapagos Genomics
MECHELEN, Belgium, May 24, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company, announces changes to its Board of Directors. In view of Galapagos' listing on Euronext Amsterdam...
GlaxoSmithKline forms Target Discovery Alliance in Asthma with Galapagos
January 05, 2005 08:13 ET
|
Galapagos Genomics
MECHELEN, Belgium, Jan. 5, 2005 (PRIMEZONE) -- Galapagos today announced that it has entered into a target licensing and multi-year target identification collaboration in respiratory and inflammatory...
Galapagos announces the separation of its drug discovery and target discovery service -- forms Galadeno(TM) as an independent business unit
September 22, 2004 08:07 ET
|
Galapagos Genomics
MECHELEN, Belgium, Sept. 22, 2004 (PRIMEZONE) -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has created a new business unit for its viral based...
Galapagos Reports Success in Identification and Validation of Proprietary Drug Targets and Moves into Drug Discovery
June 07, 2004 02:07 ET
|
Galapagos Genomics
MECHELEN, Belgium, June 7, 2004 (PRIMEZONE) -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has identified, validated and filed patent applications on...